Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Stem cell transplantation is a potentially curative treatment for sickle cell disease (SCD), but it is not feasible for most people, often due to a...
Patients with newly diagnosed multiple myeloma (MM) who received daratumumab along with the standard care regimen of bortezomib, lenalidomide, and...
Patients with relapsed or refractory acute leukemia with rearrangement in the lysine methyltransferase 2a gene, a genetic marker known as KMT2Ar, who ...
Patients with relapsed or refractory mantle cell lymphoma (MCL) who received ibrutinib in combination with venetoclax experienced significantly...
Research findings being presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition highlight new treatment approaches...
Four studies presented during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition examine how demographics and other...
Researchers report striking progress in the application of cutting-edge tools and treatments to address longstanding challenges in blood disorders...
Researchers report significant progress toward improving access to effective interventions to address blood disorders and promote healthy blood cell...
New research being presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition draws attention to previously overlooked...
New research being presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition focuses on a variety of approaches for...
esearch findings being presented during the 64th American Society of Hematology (ASH) Annual Meeting and Exposition challenge standard practices in...
Four studies presented during the 64th American Society of Hematology (ASH) Annual Meeting and Exposition uncover significant disparities in medical...
Today, the American Society of Hematology (ASH) announced the institutions that have been selected for the ASH Hematology-Focused Fellowship Training ...
Fitusiran, an experimental hemophilia therapy administered through a monthly subcutaneous injection, met its primary endpoint in a phase III trial...
A new trial found patients with diffuse large B-cell lymphoma (DLBCL) had a significantly higher likelihood of survival without disease progression...
In a phase III trial presented during the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, the chimeric antigen receptor...
As the COVID-19 pandemic continues to evolve, five studies being presented during the 63rd American Society of Hematology (ASH) Annual Meeting and...
Three studies being presented during the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition throw a spotlight on novel...
Four studies being presented during the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition point to the transformative role...
Four studies being presented during the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition highlight opportunities to better...
The ASH Research Collaborative (ASH RC), a non-profit organization established in 2018 by the American Society of Hematology (ASH), and Global Blood...
The ASH Research Collaborative (ASH RC) has announced the first 10 clinical research consortia to join the ASH RC Sickle Cell Disease Clinical Trials ...
The American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF), and...
The gene therapy etranacogene dezaparvovec substantially increased production of the blood clotting protein factor IX among 52 patients in the...
Genetic mutations linked with cancer can occur during childhood or even before birth and proliferate in the body for many years before causing cancer ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.